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Purpose: 18F-fluorodeoxyglucose positron emission tomography/computed tomog-
raphy (18F-FDG PET/CT) scans are frequently performed for the screening or stag-
ing of malignant tumors. This study aimed to assess the usefulness of 18F-FDG 
PET/CT in detection of gastric cancer recurrence after curative gastrectomy.  Mate-
rials and Methods: Eighty nine patients who had undergone curative gastrectomy 
due to gastric cancer and had 18F-FDG PET/CT and contrast CT scans within 2 
weeks for surveillance in asymptomatic patients (n = 11) or to clarify suspected re-
currence (n = 78) were consecutively collected and retrospectively analyzed. They 
had clinical follow-up for at least 12 months after PET/CT and CT scans. Results: 
Fifteen of the 89 patients (16.9%) were diagnosed with recurrent gastric cancer in 
21 organs. Forty one organs showed an increase in FDG uptake, and only 9 of these 
organs were diagnosed with recurrent gastric cancer by 18F-FDG PET/CT. The sen-
sitivity, specificity, positive predictive value, negative predictive value, and diag-
nostic accuracy of the 18F-FDG PET/CT were 42.9%, 59.7%, 29.3%, 78.2%, and 
57.3%, respectively. On the CT scan, 18 of 21 recurrent gastric cancers were detect-
ed, and 7 cases were in agreement with the 18F-FDG PET/CT. The sensitivity and 
specificity of the CT scan were 85.8% and 87.3%, respectively, which are superior 
to the 18F-FDG PET/CT. When we diagnosed a recurrence based on either 18F-FDG 
PET/CT or CT scans, the sensitivity increased to 95.2% and the specificity de-
creased to 45.6%, when compared with the contrast CT scan alone. Conclusion: 
18F-FDG PET/CT is an insufficient diagnostic method in detection of recurrence af-
ter curative gastrectomy, and even less accurate than contrast CT scan alone.
Key Words: Gastric cancer, recurrence, 18F-FDG PET/CT scan, contrast CT scan
INTRODUCTION
Radical surgical resection of gastric cancer is a considered curative treatment. 
However, the reported recurrence rate after curative surgery ranges between 22% 
and 60%.1,2 Therefore, early detection of recurrence is important in an effort to im-
prove prognosis. 
To detect recurrences, endoscopy, other imaging modalities, and tumor markers Ji Eun Lee, et al.
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Blood glucose levels were checked in patients with diabe-
tes and patients who did not know their blood glucose lev-
els prior to the injection of 18F-FDG. A PET/CT scan was 
performed only when blood glucose levels did not exceed 
150 mg/dL (8.3 mmol/L). Data acquisition was done by an 
integrated PET/CT system (Philips Gemini, DA Best, the 
Netherlands) 1 h after the 18F-FDG injections. CT scanning 
was performed prior to the PET scan from the head to the 
pelvic floor with 120 kVp, 250 mA, and a 5.3 mm section 
thickness. Next, the PET scan was performed with a 5-min 
emission acquisition per imaging level and the images were 
reconstructed. PET image data was acquired by imaging re-
construction using a Row Action Maximum Likelihood Al-
gorithm (RAMLA). A board certified nuclear radiologist re-
viewed the 18F-FDG PET/CT scans. Strong and focal FDG 
uptake combined with a delayed image was indicative of a 
recurring malignant lesion, but diffuse or segmental pat-
terns without focally increased accumulation were inter-
preted as physiologic uptakes.
　
Abdominopelvic contrast CT scan 
The patients fasted at least 6 h prior to the CT scan, and in-
gested 600-800 mL of oral contrast. Scanning from above the 
diaphragm to the greater trochanter was performed using a 
16-row multi-slice CT unit (Sensation 16; Siemens Medical 
Solutions, Erlangen, Germany), with 120 kVp, 300 mA, and 
5 mm section thickness at 7 mm/sec table speed.
　
Diagnosis of recurrent gastric cancer
The recurrence of gastric cancer was determined by a com-
bination of histopathologic diagnosis, endoscopic finding, 
tumor markers, CT scan images of the suspicious lesions 




Eighty nine consecutive patients who had undergone curative 
gastrectomy for gastric cancer and had 18F-FDG PET/CT and 
CT scans between January 2006 and September 2007 as a 
follow-up study were enrolled. Sixty two patients were male 
and 27 patients were female. Patient age ranged from 27-82 
years, the mean age being 56.4 years old (± 12.5). The dura-
tion of follow-up after surgery ranged from 12-125 months, 
and the mean duration was 34.5 months (± 24.9). The post-
have been used. However, endoscopic diagnosis has a high 
sensitivity in detecting intra-luminal recurrences of gastric 
cancer, and other imaging studies, such as a computed tomog-
raphy (CT) scan or 18f-fluorodeoxyglucose positron emission 
(18F-FDG PET) scan, are used in diagnosing local recurrences 
or distant metastases. A CT scan is the most common method 
for detecting gastric cancer recurrences, and has 76% to 93% 
sensitivity for T staging,3 and 52% to 73% sensitivity for N 
staging, but is of limited diagnostic value in diagnosing peri-
toneal or hematogenous metastases.4-6
A PET scan is another imaging modality that reflects can-
cer cell metabolism via glucose utilization using 18f-fluorode-
oxyglucose (18F-FDG) as a tracer. 18F-FDG PET scan com-
bined with CT scan (18F-FDG PET/CT) can yield more 
accurate information by stereographic reconstruction. 18F-
FDG PET/CT scans are frequently performed for staging of 
lung, colorectal, breast, head and neck carcinomas, and lym-
phomas. In gastric cancer, the FDG uptake of cancer cells is 
relatively low and the reproducibility is limited, more than in 
other malignancies. Indeed, there are only a few reports of 
the clinical role of 18F-FDG PET/CT scans in the detection of 
gastric cancer recurrence.7-11 However, the role of 18F-FDG 
PET/CT scans in detecting gastric cancer recurrence after cu-
rative gastrectomy is unclear. Therefore, we assessed the util-
ity of 18F-FDG PET/CT scans in the evaluation of gastric 
cancer recurrence after curative gastrectomy.
MATERIALS AND METHODS
Subjects
The cases of 89 patients, who had undergone curative gas-
trectomy for gastric cancer and had 18F-FDG PET/CT fol-
lowed by abdominopelvic contrast CT scans or vice versa 
within 2 weeks of the operation between January 2006 and 
September 2007, were consecutively recruited. They had 
18F-FDG PET/CT for surveillance in asymptomatic patients 
or to clarify suspected recurrence. Any patient who had 
clinical follow-up for less than 12 months after the PET/CT 
and CT scans was excluded. This study was designed to be 
a retrospective analysis based on medical records and was 
approved by the institutional review board. The 6th UICC 
TNM classification was used for gastric staging.12
18F-FDG PET/CT scan 
The patients fasted at least 4 h prior to intravenous injection 
of 370-666 MBq [10-18 mCi (0.14 mCi/kg)] 18F-FDG. The Role of 18F-FDG PET/CT in Gastric Cancer Recurrence
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common histologic type (n = 65; 73.0%), followed by sig-
net ring cell type (n = 17; 19.1%), and mucinous cell type 
(n = 7; 7.9%) (Table 1). 
Patients whom recurrence was not suspected were staged 
as 5 Ia, 3 Ib, and 3 IIIa.
　
Recurrence of gastric cancer
Recurrences were diagnosed in 15 of 89 patients (16.9%), all 
in the suspected group. The pathologic stages were as fol-
lows: II, 2 (13.3%); IIIa, 7 (46.7%); IIIb, 2 (13.3%); and IV, 4 
(26.7%). Histologically, nine patients (60.0%) showed poorly 
differentiated adenocarcinoma and five patients (33.3%) 
showed signet ring cell type, and one patient (6.7%) showed 
moderately differentiated adenocarcinoma (Table 1).
The 15 patients’ recurrences involved 21 different anatom-
ic sites. Among these, 3 involved the regional bowel, 4 in-
surgery time to 18F-FDG PET/CT ranged from 3-110 
months, and the mean interval was 24.7 months (± 22.7). 
Seventy eight patients had 18F-FDG PET/CT for clarification 
of a suspected recurrence while 11 patients had 18F-FDG 
PET/CT for surveillance without suspicion of recurrence.
The post-operative pathologic stages of gastric cancer 
were as follows: Ia, 9 (10.1%); Ib, 10 (11.2%); II, 19 (21.3%); 
IIIa, 28 (31.5%); IIIb, 10 (11.2%); and IV, 13 (14.6%). Pa-
tients with stages Ia and Ib, who had 18F-FDG PET/CT 
were suspicious for recurrence based on elevated tumor 
marker levels or regional LN enlargement on the contrast 
CT scan. All 10 patients with stage IIIb showed T3N2M0. 
Patients with stage IV included 5 patients with T4NxM0 
and 8 patients with TxN3M0. All patients with stage III or 
IV had no evidence of unresectable lymph nodes or distant 
metastasis before operation. Adenocarcinoma was the most 
Table 1. Clinicopathologic Features of Patients with Recurrent Gastric Cancer 
Patients, n (%) Patients with recurrence, n (%)
Baseline stage Ia   9 (10.1) 0 (0.0)
Ib 10 (11.2) 0 (0.0)
II 19 (21.3)   2 (13.3)
IIIa 28 (31.5)   7 (46.7)
IIIb 10 (11.2)   2 (13.3)
IV 13 (14.6)   4 (26.7)
Histologic type  Well differentiated 3 (3.4) 0 (0.0)
Moderately differentiated 15 (16.9) 1 (6.7)
Poorly differentiated 47 (52.8)   9 (60.0)
Signet ring cell 17 (19.1)   5 (33.3)
Mucinous cell 7 (7.9) 0 (0.0)
Total 89 15
Table 2. Diagnostic Imaging Studies to Detect Recurrence by Organ
Recurrence Positive diagnostic methods
n PET / CT CT scan Concordance 
Small bowel 2 0 2 0 / 2
Colon & rectum 1 0 1 0 / 1
Peritoneum 4 0 4 0 / 4
Liver 2 2 2 2 / 2
Pancreas 1 0 1 0 / 1
CBD 1 0 1 0 / 1
Ovary 1 0 1 0 / 1
Ureter 1 0 1 0 / 1
Brain 1 0 0 0 / 1
Regional LN 3 3  3 3 / 3
Distant LN 4 4  2 2 / 4
Total cases 21 9 18   7 / 21
PET, positron emission; CBD, common bile duct; LN, lymph node.Ji Eun Lee, et al.
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negative predictive value, and diagnostic accuracy of the 
18F-FDG PET/CT in the recurrence-unsuspected group were 
42.9%, 61.0%, 37.1%, 75.0%, and 57.8%, respectively. In 
contrast, there were 4 FDG uptakes at the stomach, regional 
lymph node and colon in patients without suspicion of re-
currence. Seven patients had no FDG uptake. However, 
there was no recurrence in any of the 11 patients. None of 
unsuspected recurrence patients showed recurrence and the 
sensitivity of 18F-FDG PET/CT scans was undefined. The 
specificity, positive predictive value, negative predictive val-
ue, and diagnostic accuracy were 46.2%, 0.0%, 100.0%, and 
53.8%, respectively.
Diagnostic accuracy of contrast CT in detection of 
recurrences
Twenty-seven sites were suspicious for recurrences. Eighteen 
of the 27 sites were diagnosed as true recurrent lesions (Table 
5). Eleven sites were detected only by contrast CT scan, in-
volved the peritoneum, 2 involved the liver, 3 involved the 
regional lymph node, 4 involved the distant lymph node, and 
5 involved other organs, including the pancreas, bile duct, 
ovaries, ureters, and brain (Table 2).
　
Diagnostic accuracy of 18F-FDG PET/CT in detection of 
recurrences 
Forty one sites showed increased FDG uptake. There were 
nine true recurring sites, and 29 false positive sites; three 
other sites were one primary thyroid cancer and two prima-
ry lung cancers.
A prominently high false positive rate (22 of 22 sites; 
100%) occurred in the bowel, including the remnant stom-
ach, small intestine, and large intestine. In the lymph nodes, 
7 out of 14 sites (50.0%) were diagnosed as true recurrenc-
es. In the liver, two of two suspicious sites were diagnosed 
as true recurrences (Table 3). 
In addition, two lymph nodal recurrences were only de-
tected by 18F-FDG PET/CT. There was one case involving 
cervical lymph nodal metastasis without locoregional re-
currence that was detected by 18F-FDG PET/CT (Fig. 1).  
According to histologic type, 70% (7 of 10 sites) of adeno-
carcinomas had increased FDG uptake. However, none of 
the recurrent signet ring cell carcinomas had FDG uptake.
The sensitivity, specificity, positive predictive value, nega-
tive predictive value, and diagnostic accuracy of 18F-FDG 
PET/CT scans for detecting gastric cancer recurrence after 
curative gastrectomy were 42.9%, 59.7%, 29.3%, 78.2%, 
and 57.3%, respectively (Table 4).
When the diagnostic accuracy of 18F-FDG PET/CT was 
evaluated according to the suspicion of recurrence, all 15 
patients with recurrence belonged to recurrence-suspected 
group. The sensitivity, specificity, positive predictive value, 
Table 3. Outcome of Increased FDG-Uptakes in PET/CT 
Abnormal FDG uptake  True recurrence  False recurrence Other neoplasms
Residual stomach 11 0 11
Small bowel   4 0   4
Colon & rectum   7 0   7
Peritoneum   1 0   1
Liver   2 2   0
Thyroid   1 0   0 1 thyroid ca.
Uterus   1 0   1
Regional lymph node   4 3   1
Distant lymph node 10 4   4 2 lung ca.
Total 41 9 29 3
FDG, fluorodeoxyglucose; PET, positron emission; Ca.; cancer.
Fig. 1. A case of recurring gastric cancer detected by FDG-uptake on PET/
CT. This 57 year-old man showed no suspicion of recurrence on the abdomi-
no-pelvic CT scan. However, on the whole body PET/CT scan, there was a 
high FDG-uptake on the left supraclavicular lymph node. This lesion was 
confirmed as distant nodal metastasis by biopsy. FDG, fluorodeoxyglucose; 
PET, positron emission. The Role of 18F-FDG PET/CT in Gastric Cancer Recurrence
Yonsei Med J   http://www.eymj.org   Volume 52   Number 1   January 2011 85
of recurrence on contrast CT and 18F-FDG PET/CT, and the 
other group with suspicion of recurrence on either contrast 
CT or 18F-FDG PET/CT, the sensitivity of combination rose 
to 95.2% and the specificity declined to 45.6% (Table 7).
　
DISCUSSION
Gastric cancer progresses by regional direct invasion, lym-
cluding the intestine (n = 3), peritoneum (n = 4), pancreas (n = 
1), bile duct (n = 1), ureter (n = 1), and ovary (n = 1) (Fig. 2).
Contrast CT scans showed a higher sensitivity (85.8%) 
and specificity (87.3%) than 18F-FDG PET/CT scans in de-
tection of gastric cancer recurrence (Table 6).
　
Diagnostic accuracy of combined contrast CT and 
18F-FDG PET/CT scans in detection of recurrences 
When divided into two groups, one group without suspicion 
Table 4. Diagnostic Accuracy of 
18F-FDG PET/CT in Detecting Postoperative Recurrence after Curative Gastrectomy 
True recurrence  No recurrence  Other neoplasms  Total cases
(+) FDG uptake  9 29 3 41
(-) FDG uptake  12 43 0 55
     Total cases 21 72 3 96
Sensitivity = 42.9% (9 / 21) .
Specificity = 43 / 72 = 59.7%. 
Positive predictive value = (9 + 3) / 41 = 29.3%. 
Negative predictive value = 43 / 55 = 78.2%. 
Accuracy = [(9 + 3) + 43] / 96 = 57.3%.
18F-FDG PET, 
18f-fluorodeoxyglucose positron emission.
Table 5. Outcome of Abnormalities on CT Scan by Organ
CT abnormality True recurrence False recurrence
Residual stomach 1 0 1
Small bowel 3 2 1
Colon & rectum 1 1 0
Peritoneum 5 4 1
Liver 3 2 1
Pancreas 1 1 0
CBD 1 1 0
Ureter 1 1 0
Ovary 1 1 0
Regional LN 6 3 3
Distant LN 4 2 2
Total cases 27 18 9
CBD, common bile duct; LN, lymph node.
Fig. 2. A case of recurrent gastric cancer detected by CT scan but showing no FDG-uptake on PET/CT. (A) This 52 year-old woman 
showed peritoneal carcinomatosis and right ovarian enlargement with septated cystic mass on CT scan. (B) However, on the 
18F-FDG 
PET/CT scan, there was no abnormal FDG-uptake. The recurrence was confirmed by peritoneal fluid cytology. FDG, fluorodeoxyglucose; 
PET, positron emission.
A BJi Eun Lee, et al.
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consisted of only 3.4% and 16.9% of cases. The rest of the 
cases were poorly differentiated, signet ring, or mucinous 
cell adenocarcinomas. Eighty two percent of cases had the 
Lauren classification diffuse type, and 14 of the 15 patients 
with recurrence had this same type in histologic features. 
Six of the 15 patents with recurrence had increased 18F-
FDG-uptake, but none of five recurring signet ring cell car-
cinomas had FDG uptake. This may contribute to the low 
recurrence detection rate by PET/CT.
Another possible reason for lower sensitivity is the physi-
ologic limitation of the gastrointestinal tract and peritone-
um. It is difficult to differentiate tumorous lesions from non-
tumorous lesions in the gastrointestinal tract because of the 
mucosal physiologic FDG uptake, as well as the inherent 
peristaltic movement.13 In our study, 18F-FDG PET/CT re-
vealed a high false positive rate in the gastrointestinal tract. 
We noted 10 false positive cases that had FDG uptake in 
the remnant stomach. According to conventional protocols, 
luminal expansion was not sufficient during the examination 
and SUV could be over-estimated. Drinking water before the 
examination may help solve this problem and decrease the 
false positive rate.14 This method will partly improve the di-
agnostic values of 18F-FDG PET/CT. CT scans diagnosed 4 
recurrent cases in the peritoneum, but 18F-FDG PET/CT did 
not detect any cases. Peritoneal metastasis does not make a 
lump in most cases. Instead, fine granulations are usually 
found. Contrast enhanced high resolution CT could detect 
phatic spread, and hematogenous metastasis. The most 
commonly affected organs include the regional lymph nodes, 
bowel, liver, and peritoneum. Currently, we use endoscopy, 
contrast CT scans, and serum tumor markers to evaluate re-
currence after curative gastrectomy. The contrast CT scan 
has a high sensitivity for other solid organ metastases, such 
as the liver and ovary, but a low diagnostic accuracy for 
lymphatic or peritoneal metastases. After gastrectomy and 
lymph node dissection for gastric cancer, anatomic struc-
tures may change, and a post-operative CT scan may have 
limited diagnostic value. Also, in peritoneal metastasis, oth-
er factors, such as the presence of ascites, location of me-
tastasis, and mesenteric fat, may influence the interpretation 
of CT scan images.13
In this study, we assessed the diagnostic usefulness of 
18F-FDG PET/CT scans in the evaluation of gastric cancer 
recurrences with clinical follow-up for more than 12 months 
to make sure any obscure lesions; 18F-FDG PET/CT scans 
had lower sensitivity and specificity than contrast CT scans. 
One reason for this is the histopathologic characteristics of 
gastric cancer. Adenocarcinoma, the most common patholog-
ic type of gastric cancer, has low 18F-FDG-uptake.14,15 Fur-
thermore, when taking cellular differentiation into account, 
poorly differentiated cells or signet ring cell adenocarcino-
ma progress more rapidly and has lower 18F-FDG-uptake 
than the well-differentiated cell type. In this study, unfortu-
nately, well and moderately differentiated adenocarcinomas 
Table 6. Diagnostic Accuracy of CT Scan in Detecting Postoperative Recurrence after Curative Gastrectomy 
True recurrence No recurrence Total cases
(+) CT abnormality  18   9 27
(-) CT abnormality    3 62 65
       Total cases 21 71 92
Sensitivity = 85.8% (18 / 21).
Specificity = 62 / 71 = 87.3%. 
Positive predictive value = 18 / 27 = 66.7%. 
Negative predictive value = 62 / 65 = 95.4%.
Accuracy = (18 + 62) / 92 = 87.0%
Table 7. Diagnostic Accuracy of Combined CT and 
18F-FDG PET/CT Scan 
True recurrence No recurrence Other neoplasm Total cases
(+) abnormality on PET/CT or CT scan 20 36 3   59
  (-) abnormality on PET/CT and CT scan   1 43 0   44
   Total cases 21 79 3 103
Sensitivity = 95.2% (20 / 21).
Specificity = 36 / 79 = 45.6%.
Positive predictive value = (20 + 3) / 59 = 39.0%. 
Negative predictive value = 43 / 44 = 97.7%. 
Accuracy = [(20 + 3) + 43] / 103 = 64.1%.
18F-FDG PET, 
18f-fluorodeoxyglucose positron emission.The Role of 18F-FDG PET/CT in Gastric Cancer Recurrence
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specificity was 71.4% and 64.2%, respectively. The final 
diagnostic accuracy of PET/CT was 42.8%. They conclud-
ed that additional PET/CT on contrast CT did not increase 
diagnostic accuracy in detection of recurred gastric cancer.9
On the other hand, 18F-FDG PET/CT also has the ability 
to detect other primary lymph nodes or tumors. In this study, 
we found 3 primary malignant sites in 2 of the 89 patients 
(2.2%), one in the thyroid and two in the lungs. There were 
several reports of incidental primary cancer by 18F-FDG 
PET/CT. According to one of these studies, 272 of 2,219 
cancer patients (12%) had findings of FDG uptake. An in-
vasive work-up was performed on 49% (133/272) of these 
patients. A second primary malignancy was found in 41 pa-
tients (31%). The common sites for a proven second prima-
ry malignancy were the lungs (n = 10), breast (n = 7), and 
colon (n = 5).16 Another report examined 1,912 patients and 
a second primary cancer was detected in 1.2% among sus-
pected 4.1% lesions. Proven second primary malignancies 
were found in the lungs (n = 7), thyroid (n = 6), colon (n = 
4), breast (n = 2), esophagus (n = 2), bile duct (n = 1), and 
the head and neck (n = 1).17 This suggests that the detection 
of unexpected second primary malignancy may be another 
important role of PET/CT.
There were several limitations on our study. The first was 
the small sample size, which may have produced a statisti-
cally limited value. The second was the retrospective de-
sign, so the suspicion of recurrence and proper indication of 
18F-FDG PET/CT studies were not well defined. 
In conclusion, the 18F-FDG PET/CT scan alone is an insuf-
ficient diagnostic method in the evaluation of recurrence after 
curative gastrectomy due to the low sensitivity and specifici-
ty, and demonstrated an even lower rate of accuracy than the 
contrast CT scan alone. When 18F-FDG PET/CT scan com-
bined with a CT scan diagnosed recurrence, the sensitivity 
improved a little but the specificity declined. Therefore, addi-
tional 18F-FDG PET/CT on contrast CT scan is an inadvis-
able method of detecting gastric cancer recurrence.
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